Drug Trial Radar · NCT07463521
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 27, 2026
Primary completion
Dec 1, 2028
Study completion Jan 22, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
Conditions
- Ocular Myasthenia Gravis
Interventions
RozanolixizumabDrug
Rozanolixizumab will be administered by subcutaneous infusion.
PlaceboDrug
Placebo will be administered by subcutaneous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part)Time frame: At Day 43
Locations
36 sites in 9 countries. Site status is shown where the registry gives one.
Mg0038 10104
Scottsdale, Arizona · Recruiting
Mg0038 10105
O'Fallon, Illinois · Recruiting
Mg0038 10106
Amherst, New York · Recruiting
Mg0038 10102
Cincinnati, Ohio · Recruiting
Mg0038 10103
Columbus, Ohio · Recruiting
Mg0038 10108
Greenfield, Wisconsin · Recruiting
Mg0038 10201
Montreal, Canada · Recruiting
Mg0038 31901
Beijing, China · Recruiting
Mg0038 31911
Beijing, China · Recruiting
Mg0038 31912
Beijing, China · Recruiting
Mg0038 31906
Chengdu, China · Recruiting
Mg0038 31908
Chongqing, China · Recruiting
Mg0038 31907
Nanchang, China · Recruiting
Mg0038 31902
Suzhou, China · Recruiting
Mg0038 20303
Dijon, France · Recruiting
Mg0038 20304
Nantes, France · Recruiting
Mg0038 20301
Nice, France · Recruiting
Mg0038 20302
Paris, France · Recruiting
Mg0038 20305
Paris, France · Recruiting
Mg0038 21403
Sarajishvili, Georgia · Recruiting
Mg0038 21402
Tbilisi, Georgia · Recruiting
Mg0038 20405
Rüdersdorf, Germany · Recruiting
Mg0038 31802
Kobe, Japan · Recruiting
Mg0038 31804
Minatoku, Japan · Recruiting
Mg0038 31805
Sendai, Japan · Recruiting
Mg0038 21204
Katowice, Poland · Recruiting
Mg0038 21203
Krakow, Poland · Recruiting
Mg0038 21206
Lublin, Poland · Recruiting
Mg0038 21202
Warsaw, Poland · Recruiting
Mg0038 20605
Alicante, Spain · Recruiting
Mg0038 20604
Barcelona, Spain · Recruiting
Mg0038 20607
Barcelona, Spain · Recruiting
Mg0038 20611
Madrid, Spain · Recruiting
Mg0038 20606
Málaga, Spain · Recruiting
Mg0038 20602
Murcia, Spain · Recruiting
Mg0038 20603
Seville, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.